Chi Zhang
Co-Founder & Chief Scientific Officer GT Biosciences
Dr. Chi Zhang is co-founder and CSO of GT Biosciences developing scalable precision medicines. Dr. Zhang earned his PhD in chemistry from MIT in Prof. Brad Pentelute’s lab, specializing in peptide and protein therapeutics and targeted drug delivery. He developed the π-clamp (first author Nature Chemistry paper), a novel solution for site-specific protein modification that addresses the critical issue of site-selectivity in antibody-drug conjugates (ADCs). He also bridged organometallic chemistry and protein chemistry (first author Nature paper) for creating new kinds of cyclic peptide and ADCs. He developed spatial transcriptome and proteome tools for brain analysis during his postdoctoral research in Prof. Ed Boyden’s lab. Dr. Zhang has received fellowships and awards from BMS, Regeneron, Genentech, Millipore Sigma, and Amgen, and is a recipient of the IUPAC Young Chemist Award. He has led projects in the DARPA Fold F(x) program for rapid discover and manufacturing of small protein ligands to combat biological threats. He holds four issued patents.
Seminars
- How to optimize screening approaches to rapidly evaluate large libraries of LNP compositions and identify candidates with enhanced extrahepatic tropism?
- What screening approaches are most effective for selecting and testing targeting moieties to ensure high specificity, manufacturability, and reproducible performance after LNP conjugation?
- How can AI/ML and predictive models be integrated into experimental screening workflows to improve lipid and ligand selection?
Deliveromics & GT AI for Cell Type Specific Ligand-LNP Design
- Deliveromics is a high-throughput screening platform that maps the delivery of hundreds of ligand-LNPs in vivo with cell type resolution
- GT AI designs both ligands and LNP formulations for cell-type specific delivery
- GT ligand LNPs crossed blood-brain barrier and transfected specific neuronal populations in mice
